```html

Chikungunya – Comprehensive Medical Guide

Overview

Chikungunya is an acute viral illness caused by the chikungunya virus (CHIKV), a member of the Alphavirus genus. The disease is transmitted primarily through the bite of infected Aedes mosquitoes (especially Ae. aegypti and Ae. albopictus). The word “chikungunya” comes from the Makonde language of East Africa and means “that which bends up,” describing the severe joint pain that forces patients to stoop.

While the infection can affect anyone who is bitten, it is most common in:

• People living in or traveling to tropical and subtropical regions of Africa, Asia, the Indian Ocean islands, and the Americas.
• Older adults and individuals with pre‑existing joint disease (e.g., osteoarthritis, rheumatoid arthritis), who often experience more intense and prolonged symptoms.

According to the World Health Organization (WHO), there were > 10 million suspected cases worldwide between 2015‑2022, with large outbreaks reported in India (2017), the Caribbean (2014‑2015), and Brazil (2016‑2020). In the United States, the CDC records ~ 1,500 travel‑related cases per year, most of which occur in returning travelers from the Caribbean and South America.

Symptoms

The clinical picture of chikungunya unfolds in three phases: acute, sub‑acute (or post‑acute), and chronic. Not every patient experiences all phases.

Acute Phase (Days 1–10)

• High fever – sudden onset, often > 39 °C (102 °F).
• Severe polyarthralgia – intense joint pain, typically symmetrical, affecting wrists, ankles, knees, elbows, and small hand/foot joints. Pain may be debilitating.
• Myalgia – muscle aches.
• Headache – often retro‑orbital.
• Rash – maculopapular, appearing 2–5 days after fever, usually on trunk and limbs; lasts 3–7 days.
• Fatigue – profound tiredness that can linger.
• GI symptoms – nausea, vomiting, abdominal pain, or diarrhoea (less common).

Sub‑Acute / Post‑Acute Phase (Weeks 2–12)

• Persistent joint pain that may fluctuate in intensity.
• Morning stiffness lasting > 30 minutes.
• Occasional low‑grade fever.
• Reduced ability to perform daily tasks.

Chronic Phase ( > 3 months )

• Joint pain lasting > 3 months, reported in 30‑60 % of patients, especially older adults.
• Joint swelling or effusion that mimics rheumatoid arthritis.
• Fatigue and occasional mood disturbances.

Note: Unlike dengue, severe bleeding is rare in chikungunya, but the intense arthralgia is the hallmark.

Causes and Risk Factors

Cause

CHIKV is an RNA virus transmitted to humans when an infected female Aedes mosquito takes a blood meal. The virus replicates in the mosquito’s salivary glands and is inoculated into the skin of the host.

Risk Factors

• Geographic exposure – traveling to or residing in endemic regions during peak mosquito season (rainy months).
• Outdoor activities – evening or early‑morning exposure when Aedes mosquitoes are most active.
• Living conditions – lack of window screens, air‑conditioning, or insecticide‑treated nets.
• Age – adults > 50 years experience more severe and prolonged disease.
• Pre‑existing joint disorders – amplify pain and risk of chronic arthritis.
• Pregnancy – while maternal disease is usually mild, vertical transmission can occur, especially around delivery.

Diagnosis

Diagnosing chikungunya relies on a combination of clinical presentation, epidemiologic context, and laboratory confirmation.

1. Clinical Assessment

• Sudden high fever + severe symmetric arthralgia in a person from an endemic area.
• Rash and absence of major bleeding differentiate it from dengue.

2. Laboratory Tests

• Reverse transcription polymerase chain reaction (RT‑PCR) – detects viral RNA. Most sensitive within the first 7 days of illness (positive in 80‑90 % of acute cases).
• Serology
  • IgM ELISA – becomes detectable 4–5 days after symptom onset, peaks at 3–6 weeks, and may remain for 2–3 months.
  • IgG – appears after 1–2 weeks, persists for years, indicating past infection.
• Complete blood count (CBC) – often shows normal or mildly low platelets; leukopenia may be present.
• Other tests – to rule out dengue, Zika, or other arthritogenic infections (e.g., rheumatoid factor, ANA if autoimmune disease suspected).

3. Imaging (if chronic arthritis develops)

• Joint ultrasound or MRI can reveal synovitis or effusion, helping differentiate from rheumatoid arthritis.

Treatment Options

There is no specific antiviral therapy for chikungunya; management focuses on symptom control and preventing complications.

1. Medications

• Acetaminophen (Paracetamol) – first‑line for fever and mild pain. Dose: 500 mg–1 g every 6 h (max 4 g/day).
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – ibuprofen, naproxen, or diclofenac for moderate‑severe arthralgia (avoid if dengue co‑infection is possible due to bleeding risk).
• Opioids – short‑term, low‑dose (e.g., tramadol) for breakthrough pain unresponsive to NSAIDs.
• Corticosteroids – low‑dose oral prednisone (10‑20 mg/day) may be considered in persistent severe arthritis after 2–3 weeks, tapered over 2–4 weeks.

2. Supportive Care

• Hydration – oral rehydration solution or water; intravenous fluids if vomiting or dehydration.
• Rest – especially during the first week; avoid heavy lifting or strenuous activity.
• Cold compresses – relieve joint swelling.

3. Physical Therapy & Rehabilitation

• Gentle range‑of‑motion exercises initiated after acute pain subsides.
• Strengthening programs to restore function.
• Occupational therapy for patients with prolonged disability.

4. Investigational Therapies

Clinical trials are evaluating monoclonal antibodies and antiviral agents (e.g., favipiravir), but none are currently approved.

Living with Chikungunya

Daily Management Tips

• Pace yourself – break tasks into short intervals; take frequent rest breaks.
• Heat & cold therapy – apply a warm pack for stiffness in the morning and a cold pack for swelling after activity.
• Footwear – supportive, cushioned shoes reduce joint stress.
• Nutrition – anti‑inflammatory diet (omega‑3 fatty acids, fruits, vegetables) may ease joint symptoms.
• Weight control – excess weight adds stress to weight‑bearing joints.
• Medication compliance – follow prescribed dosing; do not mix NSAIDs with alcohol.
• Monitoring – keep a symptom diary to track pain severity, triggers, and response to medications.

Psychosocial Support

Chronic pain can lead to anxiety or depression. Seek counseling, join support groups (many online for chikungunya survivors), and discuss mental health with your provider.

Prevention

Because there is no licensed vaccine (several candidates are in phase I/II trials), prevention centers on mosquito control and personal protection.

Environmental Measures

• Eliminate standing water (flower pots, buckets, tires) where Aedes larvae develop.
• Use larvicides (e.g., Bacillus thuringiensis israelensis) in water containers that cannot be emptied.
• Maintain screened windows and doors; install air‑conditioning when possible.
• Community‑wide fogging or indoor residual spraying during outbreaks (public health authority‑led).

Personal Protective Measures

• Wear long‑sleeved shirts, long pants, and socks, especially at dawn and dusk.
• Apply EPA‑registered insect repellents containing DEET (≤ 30 %), picaridin, IR3535, or oil of lemon eucalyptus on exposed skin.
• Treat clothing and gear with permethrin (permethrin‑treated uniforms for travelers).
• Sleep under mosquito‑netting if doors/windows are not screened.

Travel Advice

• Check CDC’s “Travel Health” site for current chikungunya risk in destination countries.
• Consider postponing travel to outbreak areas if you have severe arthritis or are pregnant.

Complications

Most infections are self‑limited, but complications can arise, especially in vulnerable populations.

• Chronic polyarthralgia/arthritis – persistent disabling joint pain lasting months to years.
• Neurological involvement – meningoencephalitis, Guillain‑Barré‑like syndrome (rare; <1 % of cases).
• Cardiac – myocarditis or pericarditis reported in isolated cases.
• Neonatal infection – vertical transmission can cause severe disease in newborns, including fever, irritability, and organ dysfunction.
• Exacerbation of pre‑existing conditions – e.g., worsening rheumatoid arthritis or gout.

When to Seek Emergency Care

---

Sources: World Health Organization (WHO) – Fact Sheet; Centers for Disease Control and Prevention (CDC) – Chikungunya Virus; Mayo Clinic – Symptoms & Causes; National Institutes of Health (NIH) – Chikungunya Virus; Cleveland Clinic – Chikungunya; peer‑reviewed literature: Singh et al., *Lancet Infect Dis* 2020; Bhatnagar et al., *J Clin Virol* 2022.

```